223 related articles for article (PubMed ID: 22649062)
21. Prefrontal executive function associated coupling relates to Huntington's disease stage.
Unschuld PG; Liu X; Shanahan M; Margolis RL; Bassett SS; Brandt J; Schretlen DJ; Redgrave GW; Hua J; Hock C; Reading SA; van Zijl PC; Pekar JJ; Ross CA
Cortex; 2013; 49(10):2661-73. PubMed ID: 23906595
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease.
Reynolds NC; Prost RW; Mark LP
Brain Res; 2005 Jan; 1031(1):82-9. PubMed ID: 15621015
[TBL] [Abstract][Full Text] [Related]
23. Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism.
van den Bogaard SJ; Dumas EM; Teeuwisse WM; Kan HE; Webb A; Roos RA; van der Grond J
J Neurol; 2011 Dec; 258(12):2230-9. PubMed ID: 21614431
[TBL] [Abstract][Full Text] [Related]
24. Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex.
Unschuld PG; Joel SE; Pekar JJ; Reading SA; Oishi K; McEntee J; Shanahan M; Bakker A; Margolis RL; Bassett SS; Rosenblatt A; Mori S; van Zijl PC; Ross CA; Redgrave GW
Psychiatry Res; 2012; 203(2-3):166-74. PubMed ID: 22974690
[TBL] [Abstract][Full Text] [Related]
25. Assessing impairment of executive function and psychomotor speed in premanifest and manifest Huntington's disease gene-expansion carriers.
Unmack Larsen I; Vinther-Jensen T; Gade A; Nielsen JE; Vogel A
J Int Neuropsychol Soc; 2015 Mar; 21(3):193-202. PubMed ID: 25850430
[TBL] [Abstract][Full Text] [Related]
26. Creatine supplementation lowers brain glutamate levels in Huntington's disease.
Bender A; Auer DP; Merl T; Reilmann R; Saemann P; Yassouridis A; Bender J; Weindl A; Dose M; Gasser T; Klopstock T
J Neurol; 2005 Jan; 252(1):36-41. PubMed ID: 15672208
[TBL] [Abstract][Full Text] [Related]
27. Functional magnetic resonance imaging of working memory in Huntington's disease: cross-sectional data from the IMAGE-HD study.
Georgiou-Karistianis N; Stout JC; Domínguez D JF; Carron SP; Ando A; Churchyard A; Chua P; Bohanna I; Dymowski AR; Poudel G; Egan GF
Hum Brain Mapp; 2014 May; 35(5):1847-64. PubMed ID: 23913754
[TBL] [Abstract][Full Text] [Related]
28. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.
Heikkinen T; Lehtimäki K; Vartiainen N; Puoliväli J; Hendricks SJ; Glaser JR; Bradaia A; Wadel K; Touller C; Kontkanen O; Yrjänheikki JM; Buisson B; Howland D; Beaumont V; Munoz-Sanjuan I; Park LC
PLoS One; 2012; 7(12):e50717. PubMed ID: 23284644
[TBL] [Abstract][Full Text] [Related]
29. Magnetization transfer imaging in 'premanifest' Huntington's disease.
Jurgens CK; Bos R; Luyendijk J; Witjes-Ané MN; van der Grond J; Middelkoop HA; Roos RA
J Neurol; 2010 Mar; 257(3):426-32. PubMed ID: 19823894
[TBL] [Abstract][Full Text] [Related]
30. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.
Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K
J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172
[TBL] [Abstract][Full Text] [Related]
31. Clinical correlation of striatal 1H MRS changes in Huntington's disease.
Sánchez-Pernaute R; García-Segura JM; del Barrio Alba A; Viaño J; de Yébenes JG
Neurology; 1999 Sep; 53(4):806-12. PubMed ID: 10489045
[TBL] [Abstract][Full Text] [Related]
32. In vivo imaging of brain glutamate defects in a knock-in mouse model of Huntington's disease.
Pépin J; Francelle L; Carrillo-de Sauvage MA; de Longprez L; Gipchtein P; Cambon K; Valette J; Brouillet E; Flament J
Neuroimage; 2016 Oct; 139():53-64. PubMed ID: 27318215
[TBL] [Abstract][Full Text] [Related]
33. The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease.
Johnson EB; Rees EM; Labuschagne I; Durr A; Leavitt BR; Roos RA; Reilmann R; Johnson H; Hobbs NZ; Langbehn DR; Stout JC; Tabrizi SJ; Scahill RI;
Neuropsychologia; 2015 Dec; 79(Pt A):138-46. PubMed ID: 26519555
[TBL] [Abstract][Full Text] [Related]
34. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy.
Scahill RI; Hobbs NZ; Say MJ; Bechtel N; Henley SM; Hyare H; Langbehn DR; Jones R; Leavitt BR; Roos RA; Durr A; Johnson H; Lehéricy S; Craufurd D; Kennard C; Hicks SL; Stout JC; Reilmann R; Tabrizi SJ;
Hum Brain Mapp; 2013 Mar; 34(3):519-29. PubMed ID: 22102212
[TBL] [Abstract][Full Text] [Related]
35. Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease.
Minkova L; Gregory S; Scahill RI; Abdulkadir A; Kaller CP; Peter J; Long JD; Stout JC; Reilmann R; Roos RA; Durr A; Leavitt BR; Tabrizi SJ; Klöppel S;
Neuroimage Clin; 2018; 17():312-324. PubMed ID: 29527479
[TBL] [Abstract][Full Text] [Related]
36. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion.
Margolis RL; O'Hearn E; Rosenblatt A; Willour V; Holmes SE; Franz ML; Callahan C; Hwang HS; Troncoso JC; Ross CA
Ann Neurol; 2001 Dec; 50(6):373-80. PubMed ID: 11761463
[TBL] [Abstract][Full Text] [Related]
37. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
Tabrizi SJ; Langbehn DR; Leavitt BR; Roos RA; Durr A; Craufurd D; Kennard C; Hicks SL; Fox NC; Scahill RI; Borowsky B; Tobin AJ; Rosas HD; Johnson H; Reilmann R; Landwehrmeyer B; Stout JC;
Lancet Neurol; 2009 Sep; 8(9):791-801. PubMed ID: 19646924
[TBL] [Abstract][Full Text] [Related]
38. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
[TBL] [Abstract][Full Text] [Related]
39. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.
Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA
J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington's disease.
Lowe AJ; Rodrigues FB; Arridge M; De Vita E; Johnson EB; Scahill RI; Byrne LM; Tortelli R; Heslegrave A; Zetterberg H; Wild EJ
Brain Commun; 2022; 4(6):fcac258. PubMed ID: 36382217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
